Effect of spironolactone on vascular stiffness in hemodialysis patients: a randomized crossover trial.

ABSTRACT:

Background

The role of spironolactone treatment in hemodialysis patients is debated, but a survival benefit is suggested. Mineralocorticoids and chronic kidney disease have been linked to cardiovascular fibrosis. Therefore, we hypothesized that spironolactone would affect vascular stiffness, cardiac systolic, and diastolic function in hemodialysis patients.

Methods

This was a randomized crossover study in hemodialysis patients supplemented with an echocardiographic case series. All outcomes reported here were secondary in the trial and were assessed without blinding. Block randomization and allocation determined treatment order. Participants received 50 mg spironolactone daily for 12 weeks and untreated observation for another 12 weeks. Pulse wave velocity (PWV) was measured

SUBMITTER: Eklund M 

PROVIDER: S-EPMC9169545 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature